News - 13 Mar `24Lessons In Marketing: How To Sell A Disease To Big Pharma

New

Lessons In Marketing: How To Sell A Disease To Big Pharma

Seeing Incyte’s “See What’s Possible” campaign — complete with larger-than-life vitiligo models at the AAD meeting in San Diego — was a milestone for our community.

For years, vitiligo flew below the healthcare industry’s radar. Today, it’s front-and-center: the first FDA-approved therapy is on the market, and more than 40 companies are investing in vitiligo R&D.

That momentum didn’t appear by chance; it grew from steady advocacy, data-driven storytelling, and a lot of patient and caregiver voices refusing to be invisible.

It’s proof that even a small non-profit like VRF can help shift perceptions and priorities across an entire field. We’re even considering a white paper on the journey, with the working title “How to Bring an Overlooked Disease to Pharma’s Attention.”

If you’d like to contribute insights or client-side perspectives, let us know!

— Yan Valle

CEO, Vitiligo Research Foundation | Author, A No-Nonsense Guide to Vitiligo

Vitiligo marketing

AAD, 2024

AAD, 2025

 



      FAQOther Questions

      • Is there a traditional medicine to treat vitiligo?

        Traditional remedies can be helpful for managing stress or general metabolic health, but when it comes to vitiligo, the evidence is limited. While some natural supplements provi...

      • How to get insurance coverage for vitiligo treatments?

        Getting insurance coverage for vitiligo treatments can be challenging, but there are several steps you can take to improve your chances For a more in-depth look, check out our u...

      • Red Wine and Vitiligo

        Recent research has explored whether moderate red wine consumption might influence vitiligo risk, especially through genetic studies and large population data. What the Genetic ...